

The kisspeptin signalling pathway and its role in breast cancer biology

Udochi Felicia Azubuiké^{1, 2}, Claire Newton^{2, 3} and Iman van den Bout^{1, 2}

1. Department of Physiology, University of Pretoria, South Africa.
2. Centre for Neuroendocrinology, University of Pretoria, South Africa.
3. Department of Immunology, University of Pretoria, South Africa.

INTRODUCTION

Kisspeptin is a neuropeptide encoded by the metastasis suppressor gene, *KISS1*. It functions through its cognate receptor, KISS1R. The activation of KISS1R by kisspeptin results in ERK1/2 activation, protein kinase B activation, calcium mobilization and inositol-1,4,5-triphosphate accumulation. Kisspeptin and KISS1R expression/activity inhibits metastasis in melanoma, pancreatic, lung, bladder, and ovarian cancers. However, in breast cancer, controversy

remains with contradictory reports assigning pro- or anti-metastatic properties to kisspeptin. This study aims to shed light on the reasons for the contradictory role of kisspeptin/KISS1R in breast cancer by investigating the intracellular signalling pathways that are activated in response to kisspeptin signalling in breast cancer cell lines and determining their role in cell migration and invasion.

METHODS





KISS1R expression: Expression of KISS1R in two triple-negative breast cancer cell lines, BT-20 and MDA-MB-231, was determined through Western blotting, using an anti-KISS1R antibody. β -tubulin was used as a loading control.

ERK1/2 phosphorylation: BT-20 and MDA-MB-231 cell lines were stimulated with kisspeptin (KP-10; 100 nM) for 5, 10, 30, 45 or 60 min, at 37°C. Vehicle-treated negative controls were included. Following stimulation, cells were lysed and ERK1/2 phosphorylation was assessed through Western blotting, using an anti-ERK1/2 antibody. Measurement of total-ERK1/2 was used as an internal control. For measurement of the effects of β -arrestin inhibition, cells

were pre-treated for 30 mins in the presence/absence of a range of concentrations of a β -arrestin 1/2 inhibitor (barbadin) prior to stimulation with KP-10 for 60 min.

Cell migration: A confluent monolayer of BT-20 and MDA-MB-231 cell lines was scratched with a 200 μ l pipette tip and then treated with media only, vehicle or 100 nM KP-10 and incubated for 18 hrs at 37°C. Images of the scratch were taken on the day the scratch was created (0 hrs) and 18 hrs later using a Zeiss Axiovert microscope.

RESULTS



DISCUSSION AND CONCLUSIONS

The breast cancer cell lines, BT-20 and MDA-MB-231, which are both triple negative breast but non-metastatic and metastatic, respectively, express endogenous KISS1R. However, the BT-20 cell line had a much higher level of expression and KP-10 was able to activate ERK1/2 phosphorylation in this cell line but not the MDA-MB-231 cells. The late phase of ERK1/2 phosphorylation in the BT-20 cells is dependent on beta-arrestin1/2, as shown by decrease in ERK1/2 phosphorylation in the cells co-treated with Barbadin and KP-10. Finally, even though the MDA-MB-231 cell line was unable to activate ERK1/2 phosphorylation, there was an increase in the migration of MDA-MB-231 cells (but not BT-20 cells) when stimulated with KP-10. This data suggests that there could potentially be another signalling pathway in the MDA-MB-231 cells that is responsible for the increase in migration as shown by the decrease in the gap of KP-10 treated cells compared to the untreated cells.

Our previous data showed that the decrease in the gap is not due to cell growth.